Hims & Hers Dips Into Men’s Cardiovascular Health
Hims & Hers can now provide treatment to men for cardiovascular issues, the company recently announced. This treatment combines sexual health and heart health together in a single pill.
Eko Launches Heart Disease Detection Platform CEO Calls ‘Shazam for Heartbeats’
Eko recently launched an AI-powered software that its CEO describes as "Shazam for heartbeats." The platform connects with Eko's digital stethoscopes and identifies whether or not a patient's heart sounds are indicative of disease.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Genetesis rakes in $17.5M as its heart disease test prepares for market entry
Medical imaging company Genetesis recently closed a $17.5 million Series C funding round, bringing its total funding to date to more than $40 million. Most of the funds will go toward clinical trials for the company's 5-minute test to detect ischemic heart disease, which uses magnetocardiography. Genetesis anticipates the test entering the market in early 2023.
AstraZeneca drops Ionis-partnered heart drug after Phase 2 success isn’t good enough
An Ionis Pharmaceuticals heart disease drug beat a placebo in a mid-stage clinical trial, but partner AstraZeneca has decided it won’t advance the genetic medicine to a larger Phase 3 test. The results were apparently not enough to set the Ionis therapy apart from commercialized cholesterol-lowering drugs that address the same protein target.
Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal
Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4 billion acquisition of Array Biopharma in 2019.
Health equity is the solution to rising heart disease deaths
A better coronary artery stent cannot help a patient who cannot afford it, does not know they need it, doesn’t have a doctor who can make a diagnosis and identify that need. To help these patients, we urgently need to look at health equity.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Met with AWS funding, Oben Health seeks to treat hypertension in at-risk groups without medication or surgery
Oben Health, a San Francisco-based company developing a digital treatment platform to fight heart disease without medication or surgery, recently received funding from AWS' accelerator for early-stage startups led by founders from underrepresented groups. The startup will use the money to scale its platform and help conduct a pilot program to better understand its model's clinical validity.
Eko unveils its newly redesigned app aimed at detecting heart disease early
The Eko App uses automated disease detection software and is paired with the company's line of smart stethoscopes to analyze heart sounds with FDA-cleared AI algorithms. The redesigned app includes a range of new features to analyze heart sounds and cardiac rhythm for potential problems, the company said.
ViVE conference highlights commitment to health equity, previews the next chapter of interoperability
The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.
Can remote monitoring flag patients with AFib better than checkups? Scripps clinical trial seeks answer
Dr. Eric Topol, director of Scripps Translational Science Institute, said: "The mSToPS trial has the potential to upgrade and refine our approach in screening for heart arrhythmias, and at the same time demonstrate the value of large, real-world clinical trials using digital medicine technologies.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Optos retinal imaging camera helped save eye doctor from fatal heart attack (to his own surprise)
Examining the retina is not just useful for vision care. With high-powered camera capabilities, evidence of a blocked artery in the heart are even visible.
Heart disease startup MyoKardia files for IPO
Bay Area startup MyoKardia just filed for an IPO with the SEC for its precision medicine approach to genetic heart disease. Specifically, it's developing small molecule drugs to treat cardiomyopathies.
A closer look at TEXT ME clinical trial reveals 5 ways to improve clinical validation of apps
Among the observations: it's not good enough to look at apps as a standalone intervention strategy.
CONVERGE: Population medicine has been a spectacular failure, but payers are hindering innovation
Susan Hertzberg, Boston Heart Diagnostics CEO said although genomic sequencing holds a lot of promise beyond cancer treatment, "right here, right now, we have not optimized or used fully what's available."
69% of doctors believe parents are either completely or mostly to blame for childhood obesity
When it comes to childhood obesity, who is to blame?